NSABP B-59
Select A Category

NSABP PROTOCOL B-59/GBG 96-GeparDouze

A Randomized, Double-Blind, Phase III Clinical Trial of Neoadjuvant Chemotherapy with Atezolizumab or Placebo in Patients with Triple-Negative Breast Cancer Followed by Adjuvant Continuation of Atezolizumab or Placebo

Primary Objective: To determine whether the addition of atezolizumab to chemotherapy (weekly paclitaxel plus carboplatin followed by AC or EC) improves pathologic complete response in the breast and post-therapy lymph nodes evaluated histologically (pCR breast and nodes) in patients with triple-negative breast cancer.

Patient Population: patients with high risk triple-negative breast cancer

Target Accrual: 1520 patients

Status: Recruiting participants

ClinicalTrials.gov Identifier: NCT03281954